Related Experiment Video
Updated: Apr 29, 2026

Zebrafish Model of Neuroblastoma Metastasis
Published on: March 14, 2021
Flotillin-1 regulates oncogenic signaling in neuroblastoma cells by regulating ALK membrane association
Arata Tomiyama1, Takamasa Uekita2, Reiko Kamata3
1Authors' Affiliations: Division of Metastasis and Invasion Signaling, National Cancer Center Research Institute; Department of Neurosurgery, National Defense Medical College, Saitama;
Abstract:
Neuroblastomas harbor mutations in the nonreceptor anaplastic lymphoma kinase (ALK) in 8% to 9% of cases where they serve as oncogenic drivers. Strategies to reduce ALK activity offer clinical interest based on initial findings with ALK kinase inhibitors. In this study, we characterized phosphotyrosine-containing proteins associated with ALK to gain mechanistic insights in this setting. Flotillin-1 (FLOT1), a plasma membrane protein involved in endocytosis, was identified as a binding partner of ALK. RNAi-mediated attenuation of FLOT1 expression in neuroblastoma cells caused ALK dissociation from endosomes along with membrane accumulation of ALK, thereby triggering activation of ALK and downstream effector signals. These features enhanced the malignant properties of neuroblastoma cells in vitro and in vivo. Conversely, oncogenic ALK mutants showed less binding affinity to FLOT1 than wild-type ALK. Clinically, lower expression levels of FLOT1 were documented in highly malignant subgroups of human neuroblastoma specimens. Taken together, our findings suggest that attenuation of FLOT1-ALK binding drives malignant phenotypes of neuroblastoma by activating ALK signaling.
Insights
Reduced flotillin-1 (FLOT1) binding to anaplastic lymphoma kinase (ALK) in neuroblastoma enhances ALK signaling and tumor malignancy. Lower FLOT1 levels correlate with aggressive neuroblastoma, suggesting FLOT1-ALK interaction as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Anaplastic lymphoma kinase (ALK) mutations drive neuroblastoma in 8-9% of cases.
- Targeting ALK activity is a promising therapeutic strategy for neuroblastoma.
Purpose of the Study:
- To investigate proteins interacting with ALK to understand its oncogenic mechanisms.
- To identify novel therapeutic targets for neuroblastoma by characterizing ALK's binding partners.
Main Methods:
- Proteomic analysis to identify ALK-associated phosphotyrosine proteins.
- RNA interference (RNAi) to modulate flotillin-1 (FLOT1) expression in neuroblastoma cells.
- In vitro and in vivo assays to assess neuroblastoma cell malignancy and ALK signaling.
Main Results:
- Flotillin-1 (FLOT1) was identified as an ALK binding partner involved in endocytosis.
- Reduced FLOT1 expression led to ALK accumulation at the membrane, activating ALK signaling and enhancing neuroblastoma malignancy.
- Oncogenic ALK mutants exhibited reduced binding affinity to FLOT1 compared to wild-type ALK.
- Lower FLOT1 expression correlated with higher malignancy in human neuroblastoma specimens.
Conclusions:
- FLOT1-ALK interaction is crucial for regulating ALK activity and neuroblastoma progression.
- Disruption of FLOT1-ALK binding promotes malignant phenotypes by activating ALK signaling.
- FLOT1 represents a potential therapeutic target for neuroblastoma treatment.
More Related Videos
Related Concept Videos
Intracellular Signaling Affects Focal Adhesions
Some...
Regulation of Angiogenesis and Blood Supply
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Cell Motility through Blebbing
Blebbing Through the Matrix
In multicellular...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Cell Polarization by Rho Proteins

